New Biotech Business Models From 1999
This article was originally published in Start Up
Advice of Counsel predicts the seven new business models that are likely to predominate in the months ahead, including "made to order" service deals; second-generation database companies; technology transfer from biotechs to big pharma; building a company to sell; holding onto a share of the upside of a late-stage product; skipping the high-risk phases of drug development; and diversifying the risk-reward tradeoff.
You may also be interested in...
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.
Venture-backed biotech companies are increasingly seeking to commercialize drugs that qualify for orphan drug protection from the FDA; is this business model a good idea?
Biomarkers are being used now across the whole pharmaceutical value chain, but it's unlikely we'll see a surge in the number of VC-backed biomarker discovery start-ups until the business models are proven.